AzTrials
AzTrials

Post Operative PainPhase 4NCT05993975

Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine

A Phase 4 study testing Bupivacain 0.5% and Dexmedetomidine Hydrochloride in people with Post Operative Pain, run by Sindh Institute of Urology and Transplantation at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients will be enrolled in one of the two groups using a computer-generated random number table: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will receive 1.2 mL of 0.5% hyperbaric bupivacaine (6 mg) along with 0.3 mL (3 μg )of dexmedetomidine (total 1.5 mL). Read more about this study

Who is it for?
Ages 50 to 80 years, men onlyHealthy volunteers can take part
Conditions the study is for
Post Operative Pain
What is being tested?
Bupivacain 0.5% and Dexmedetomidine Hydrochloride
Could I receive a placebo?
No, everyone receives an active treatment
How many people
108 participants
Where
1 sitePakistan
Study dates
20 Jul 2021to 18 Feb 2022
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 80 years
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • ASA I to ASA II
  • Age 50 to 80 years old
  • Height between 155cm and 175 cm

Who cannot join

  • History of spine surgery or the presence of an infectious focus on the back
  • Patient's refusal to undergo a spinal anaesthesia
  • Hypersensitivity to bupivacaine or dexmedetomidine
  • Patients taking drugs of abuse or narcotic analgesics
  • Diabetic neuropathy
  • History of bleeding disorders
Show all 13Show fewer
  • Oral/intravenous anticoagulant therapy
  • History of arrhythmias or labile hypertension
  • Unco-operative patients
  • Hearing defect
  • ASA III and IV
  • Central or peripheral nervous system disorders
  • Severe hypovolemia

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • Syed Muhammad Abbas

    Karachi, Sindh, 74200

Other trials in Pakistan

About this study

Official title: Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine on Hemodynamic Parameters in Patients Undergoing Transurethral Resection of the Prostate

Patients will be enrolled in one of the two groups using a computer-generated random number table: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will receive 1.2 mL of 0.5% hyperbaric bupivacaine (6 mg) along with 0.3 mL (3 μg )of dexmedetomidine (total 1.5 mL).

Read the detailed description

After approval of the synopsis and permission from the hospital ethics committee, all patients meeting the inclusion criteria will be included in the study. Patients will be instructed not to consume solid food after midnight before surgery and to take clear liquids up to 2 hours before surgery. Using a computer-generated random number table, patients will be enrolled in one of the two groups: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will receive 1.2 mL of 0.5% hyperbaric bupivacaine (6 mg) along with 0.3 mL (5 μg )of dexmedetomidine (total of 1.5 mL). They will be randomly allocated into two groups using the sealed envelope technique by a person blinded to the procedure. The study medication will be prepared by an anaesthesiologist not involved in the study and another anaesthesiologist performing the spinal block will record the intraoperative and postoperative data. On arrival at the Operating Room (OR) monitors like a non-invasive blood pressure monitor (NIBP), peripheral oxygen saturation monitor (SpO2), and electrocardiography monitor (ECG) having lead II will be attached. All the baseline values of blood pressure (SBP, DBP, and MAP), heart rate and rhythm, and SPO2 will be observed and recorded. An intravenous (IV) line will be established with an 18-gauge cannula. The study drug solutions will look identical. For Group I, 7.5 mg(1.5 mL) of 0.5% hyperbaric bupivacaine hydrochloride will be drawn in a 3 mL BD syringe. For Group II, 6mg (1.3 mL) of 0.5% hyperbaric bupivacaine hydrochloride will be drawn in a 3 mL BD syringe. By using an insulin syringe, 0.3 mL (3 μg) of Dexmedetomidine (preservative free) 100 μg/mL will be added to the 6 mg (1.3 mL) of hyperbaric bupivacaine under complete aseptic conditions to bring the total volume to 1.5 mL. The total volume of drug solutions will be 1.5 mL in each group.

Local infiltration of the skin with 2mL of 2% lidocaine will be done to decrease the discomfort caused by the spinal needle. A spinal puncture will be performed at L3-L4 or L4-L5 with a midline approach using a 25-gauge Quincke needle in the sitting position. After verification of clear and free flow of cerebrospinal fluid, the drug will be administered and the patients will be placed in the supine position Vitals will be monitored Heart Rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), respiratory rate (RR), oxygen saturation (SpO2) for every 5 minutes till the end of surgery. If mean arterial pressure (MAP) decreases below 65 mmHg or the Heart rate falls below 65 beats per minute then intravenous vasopressors will be given. The sensory block levels will be checked on the bilateral mid-clavicular line with a pin prick with a blunt needle every 2 min from the time of drug injection until the sensory level achieves up to T10 level.

In contrast, the motor block will be assessed using the modified Bromage scale. The surgeon will be asked to start the surgery when the sensory block has reached the T10 level. After completion of the surgery, the patient will be shifted to the PACU and monitored for 3 hours with continuous ECG monitoring and intermittent non-invasive blood pressure monitoring at 5-minute intervals. All untoward events like shivering, nausea vomiting, sedation, and respiratory depression will be monitored and recorded in the operating room as well as in the recovery room.

All data will be recorded on Performa attached as Annex A after the consultant anesthetist confirms.

Being tested
Bupivacain 0.5%, Dexmedetomidine Hydrochloride
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bupivacain 0.5%Drug

    Also called Pure Bupivacain 0.5%

    Bupivacaine hydrochloride was given without any adjuvant

  • Dexmedetomidine HydrochlorideDrug

    Also called Dexmedetomidine 5 microgram

    Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride

Study groups in NCT05993975
Study groupRoleWhat they receive
BUPIPUREActive comparatorHyperbaric Bupivacaine 0.5% (1.5 ml/7.5 mg) to be given intrathecally Total volume 1.5 mL
Receives: Drug: Bupivacain 0.5%
BUPI-DEXExperimentalHyperbaric Bupivacaine 0.5% (1.2 ml/6 mg)+Dexmedetomidine (0.3 mL) 3 microgram intrathecally. Total volume 1.5 mL
Receives: Drug: Bupivacain 0.5%; Drug: Dexmedetomidine Hydrochloride

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Height of sensory block

    Dermatome level having absence of cold sensation

    Measured: 0 to 4 hours

  2. Motor block

    According to Bromage scores

    Grade Criteria I Free movement of legs and feet II Just able to flex knees with free movement of feet III Unable to flex knees, but with free movement of feet IV Unable to move legs or feet

    we need paralysis of both legs (Bromage score IV) for surgery

    Measured: 0 to 4 hours

  3. Time for 2 segment regression of sensory block

    Dermatome level having absence of cold sensation

    Measured: 0 to 4 hours

  4. Heart rate

    By anaesthesia ECG monitor

    Measured: 0 to 4 hours

  5. Mean Blood pressure

    Non invasive blood pressure monitoring devise

    Measured: 0 to 4 hours

Secondary outcomes (1)
  1. Shivering

    Bedside Shivering Assessment Score (BSAS) grade 0, if there is no shivering grade 1 if there is no muscle contraction but mild fasciculation of face or neck or peripheral vasoconstriction but no visible shivering, grade 2 if there is a visible muscular activity in only one muscle group, grade 3 if the muscular activity is in more than one muscle group but not generalized grade 4 if gross muscular activity involving the entire body.

    Grade 0 is better, increase in grade (0 -> 4) means worsening

    Measured: 0 to 4 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Aug 2023
  2. Study start20 Jul 2021
  3. Primary completion18 Feb 2022
  4. Study completion18 Feb 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
Group BUPPURE will receive 1.5 ml of hyperbaric 0.5% bupivacaine (1.5 ml/7.5 mg) whereas the BUPIDEX group will receive Dexmedetomidine 3 micrograms (0.3mL)with hyperbaric 0.5% bupivacaine (1.2 ml/6 mg) to be given to one group.
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
108 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05993975
Sponsor's protocol ID
SAbbas
Status last verified
Oct 2023
First submitted
1 Jul 2023
Last updated
31 Oct 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Bupivacain 0.5% and Dexmedetomidine Hydrochloride in people with Post Operative Pain, run by Sindh Institute of Urology and Transplantation at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Height of sensory block (time frame: 0 to 4 hours). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in